drug · protein
tirzepatide
pre_registrationupdated 6mo agoby Eli Lilly and Co🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 6Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.
targets
Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor
all catalysts(0)
nothing on the calendar yet
Trials studying tirzepatide
- phase4A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
- phase1Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- phase3A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
- phase3Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
- phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
News(10)
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 12h ago
- STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and moreDuring July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous yearstat · 13h ago
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 3d ago
- STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and moreA deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lillystat · 3d ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 3d ago
- Deep dive: Cardiovascular calamities and catalystsBioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.biospace · 4d ago
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 4d ago
- STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and moreThe FDA has shelved the fast-track drug review initiative launched in June 2025 by former Commissioner Marty Makarystat · 4d ago
- STAT+: Most-favored nations policy makes drugmakers rethink launches abroadDrug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:stat · 5d ago
- STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and moreIncoming Democratic chairs of key congressional committees have taken a new step toward investigating most-favored nation drug pricing agreementsstat · 5d ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that